MedTrace Logo

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

NCT05170334 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2026-04-06

No results posted yet for this study

Summary

This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.

Conditions

  • Metastatic Uveal Melanoma

Interventions

DRUG

Binimetinib

Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.

DRUG

Belinostat

Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Acrotech Biopharma Inc.

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Ahmad Tarhini, MD, PhD · Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2025-12-01
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05170334 on ClinicalTrials.gov